Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gliosarcoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Gliosarcoma - Pipeline Review, H1 2015', provides an overview of the Gliosarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gliosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gliosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gliosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gliosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gliosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gliosarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Gliosarcoma - Overview 7 Pipeline Products for Gliosarcoma - Comparative Analysis 8 Gliosarcoma - Therapeutics under Development by Companies 9 Gliosarcoma - Therapeutics under Investigation by Universities/Institutes 10 Gliosarcoma - Pipeline Products Glance 11 Clinical Stage Products 11 Gliosarcoma - Products under Development by Companies 12 Gliosarcoma - Products under Investigation by Universities/Institutes 13 Gliosarcoma - Companies Involved in Therapeutics Development 14 Amgen Inc. 14 Burzynski Research Institute, Inc. 15 Celgene Corporation 16 Merck & Co., Inc. 17 Millennium Pharmaceuticals, Inc. 18 NewLink Genetics Corporation 19 Sanofi 20 Gliosarcoma - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 alisertib - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Antineoplaston Therapy - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CC-122 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 DNX-2401 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 indoximod - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 lonafarnib - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 plerixafor - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 rilotumumab - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SGT-53 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Stem Cell Therapy for Glioma - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Gliosarcoma - Recent Pipeline Updates 52 Gliosarcoma - Dormant Projects 59 Gliosarcoma - Product Development Milestones 60 Featured News & Press Releases 60 Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for Gliosarcoma, H1 2015 7 Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Gliosarcoma - Pipeline by Amgen Inc., H1 2015 14 Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H1 2015 15 Gliosarcoma - Pipeline by Celgene Corporation, H1 2015 16 Gliosarcoma - Pipeline by Merck & Co., Inc., H1 2015 17 Gliosarcoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 18 Gliosarcoma - Pipeline by NewLink Genetics Corporation, H1 2015 19 Gliosarcoma - Pipeline by Sanofi, H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Gliosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 52 Gliosarcoma - Dormant Projects, H1 2015 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.